AbbVie is a global, research-based biopharmaceutical company. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
Company Growth (employees)
North Chicago, US
Size (employees)
30,000 (est)+8%
AbbVie was founded in 2013 and is headquartered in North Chicago, US

Key People at AbbVie

Richard A. Gonzalez

Richard A. Gonzalez

Chairman of the Board and Chief Executive Officer

AbbVie Office Locations

AbbVie has an office in North Chicago
North Chicago, US (HQ)
1 Waukegan Rd

AbbVie Data and Metrics

AbbVie Financial Metrics

AbbVie's revenue was reported to be $25.6 b in FY, 2016 which is a 12% increase from the previous period.

Revenue (FY, 2016)

25.6 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

19.8 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

6 b

Market capitalization (17-Aug-2017)

111.8 b

Cash (31-Dec-2016)

5.1 b


143.5 b
AbbVie's current market capitalization is $111.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


18.8 b20 b22.9 b25.6 b

Revenue growth, %


Cost of goods sold

4.6 b4.4 b4.5 b5.8 b

Gross profit

14.2 b15.5 b18.4 b19.8 b

Gross profit Margin, %


Operating expense total

13.1 b16.5 b15.3 b16.3 b

Interest expense

(278 m)(391 m)(686 m)(965 m)

Income tax expense

1.2 b595 m1.5 b1.9 b

Net Income

4.1 b1.8 b5.1 b6 b
USDFY, 2013FY, 2014FY, 2015FY, 2016


9.6 b8.3 b8.4 b5.1 b

Accounts Receivable

3.9 b3.7 b4.7 b4.8 b


1.2 b1.1 b1.7 b1.4 b

Current Assets

17.8 b16.1 b16.3 b16.2 b


2.3 b2.5 b2.6 b2.6 b


6.3 b5.9 b13.2 b15.4 b

Total Assets

29.2 b27.5 b53.1 b66.1 b

Total Debt

3.9 b4.3 b29.6 b36.8 b

Current Liabilities

6.9 b11.4 b10.9 b9.8 b

Additional Paid-in Capital

3.7 b4.2 b13.1 b13.7 b

Retained Earnings

1.6 b535 m2.2 b4.4 b

Total Equity

4.5 b1.7 b3.9 b4.6 b

Debt to Equity Ratio

0.9 x2.4 x7.5 x7.9 x

Debt to Assets Ratio

0.1 x0.2 x0.6 x0.6 x

Financial Leverage

6.5 x15.8 x13.4 x14.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.1 b1.8 b5.1 b6 b

Accounts Receivable

681 m(172 m)(1.1 b)(71 m)


(56 m)(203 m)(434 m)(38 m)

Accounts Payable

(426 m)(193 m)1.5 b(1.2 b)

Cash From Operating Activities

6.3 b3.5 b7.5 b7 b

Cash From Investing Activities

879 m(926 m)(12.9 b)(6.1 b)

Short-term Borrowings

(601 m)12 m(19 m)(29 m)

Dividends Paid

(2.6 b)(2.7 b)(3.3 b)(3.7 b)

Cash From Financing Activities

(3.4 b)(3.3 b)5.8 b(3.9 b)

Income Taxes Paid

1.3 b498 m1.1 b3.6 b
USDY, 2016


20.4 x


1 m


7.9 x


0.6 x

Financial Leverage

14.3 x

AbbVie Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Stem CentRxApril 28, 2016$5.8 b

AbbVie Market Value History

AbbVie Median Salaries

Source: 442 public H-1B filings from AbbVie

Traffic Overview of AbbVie

AbbVie Online and Social Media Presence

AbbVie News and Updates

Elliott Associates sues AbbVie over failed bid for Shire

Aug 5 (Reuters) - AbbVie Inc said hedge fund Elliott Associates LP has sued the pharmaceuticals company alleging that it had made misrepresentations and omissions related to a failed attempt to buy Dublin-based Shire Plc .

Two of the World’s Best-Selling Drugs Are Headed for a Lot More Competition

Copycats of AbbVie's Humira and Amgen's Enbrel may soon win FDA approval.

AbbVie Company Life and Culture

You may also be interested in